Frank Rimerman Advisors LLC Cuts Holdings in Stryker Co. (NYSE:SYK)

Frank Rimerman Advisors LLC decreased its holdings in shares of Stryker Co. (NYSE:SYK) by 0.8% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 5,928 shares of the medical technology company’s stock after selling 49 shares during the quarter. Frank Rimerman Advisors LLC’s holdings in Stryker were worth $2,134,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in SYK. Kohmann Bosshard Financial Services LLC purchased a new position in Stryker in the fourth quarter valued at about $25,000. Dunhill Financial LLC increased its position in shares of Stryker by 94.9% during the third quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock worth $27,000 after acquiring an additional 37 shares during the last quarter. Rakuten Securities Inc. increased its position in shares of Stryker by 618.2% during the fourth quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company’s stock worth $28,000 after acquiring an additional 68 shares during the last quarter. Centricity Wealth Management LLC purchased a new stake in shares of Stryker during the fourth quarter worth about $30,000. Finally, BankPlus Trust Department purchased a new stake in shares of Stryker during the fourth quarter worth about $33,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Insider Activity

In other Stryker news, Director Ronda E. Stryker sold 201,392 shares of Stryker stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $392.24, for a total value of $78,993,998.08. Following the transaction, the director now owns 3,642,075 shares in the company, valued at $1,428,567,498. The trade was a 5.24 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Allan C. Golston sold 2,458 shares of the firm’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total value of $941,586.06. Following the completion of the sale, the director now directly owns 14,895 shares of the company’s stock, valued at approximately $5,705,827.65. This represents a 14.16 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 5.90% of the company’s stock.

Stryker Trading Up 1.7 %

Shares of Stryker stock opened at $369.96 on Friday. Stryker Co. has a 1 year low of $314.93 and a 1 year high of $406.19. The firm has a market cap of $141.17 billion, a PE ratio of 47.68, a PEG ratio of 2.93 and a beta of 0.95. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32. The company has a 50 day simple moving average of $383.04 and a two-hundred day simple moving average of $373.37.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same quarter in the prior year, the company posted $3.46 EPS. Analysts expect that Stryker Co. will post 13.47 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be issued a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a yield of 0.91%. The ex-dividend date is Monday, March 31st. Stryker’s dividend payout ratio (DPR) is currently 43.30%.

Wall Street Analysts Forecast Growth

SYK has been the subject of a number of research reports. StockNews.com downgraded Stryker from a “buy” rating to a “hold” rating in a research note on Thursday, March 6th. JMP Securities reiterated a “market perform” rating on shares of Stryker in a research report on Tuesday, February 18th. Needham & Company LLC restated a “buy” rating and set a $442.00 price target on shares of Stryker in a report on Wednesday, January 29th. Argus set a $450.00 price objective on shares of Stryker in a report on Monday, February 3rd. Finally, Stifel Nicolaus boosted their target price on shares of Stryker from $400.00 to $440.00 and gave the stock a “buy” rating in a research report on Wednesday, January 29th. Five investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $421.90.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.